Lv11
20 积分 2022-11-02 加入
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans
4小时前
待确认
How selective are clinical CDK4/6 inhibitors?
4小时前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
1个月前
已完结
Targeted therapy in TNBC: Exploring the role of antibody-drug conjugates with a focus on sacituzumab govitecan
1个月前
已完结
P265: Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
1个月前
已完结
P265: Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
1个月前
已完结
P265: Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
2个月前
已完结
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review
2个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
3个月前
已完结
皖公网安备34019202002308
